What is Thermalin?
Thermalin is a biotechnology firm dedicated to the innovation of insulin delivery and molecular design. The company's research pipeline, rooted in the academic excellence of Dr. Michael Weiss at Case Western Reserve University, focuses on high-impact solutions including ultra-rapid-acting insulin, temperature-stable formulations, and glucose-responsive delivery systems. By addressing the limitations of current insulin therapies, Thermalin aims to improve patient outcomes through advanced molecular engineering. The company's market position is bolstered by a history of support from prestigious organizations such as the JDRF and the Leona M. and Harry B. Helmsley Charitable Trust, reflecting a strong alignment with global health initiatives aimed at mitigating the burden of chronic metabolic diseases.
How much funding has Thermalin raised?
Thermalin has raised a total of $14.3M across 6 funding rounds:
Other Financing Round
$2.2M
Series A
$2.9M
Unspecified
$2.5M
Series B
$5.9M
Debt
$350K
Debt
$429K
Other Financing Round (2010): $2.2M with participation from JumpStart
Series A (2011): $2.9M led by JumpStart
Unspecified (2012): $2.5M, investors not publicly disclosed
Series B (2014): $5.9M featuring Undisclosed
Debt (2020): $350K backed by PPP
Debt (2021): $429K with participation from PPP
Key Investors in Thermalin
JumpStart
JumpStart Inc. is a venture development organization providing capital, services and connections to help entrepreneurs grow, researchers commercialize and corporations innovate.
Undisclosed Investors
PPP
Public-Private Partnership
What's next for Thermalin?
With the infusion of recent capital, Thermalin is well-positioned to accelerate its preclinical programs and transition toward critical clinical development phases. The strategic roadmap emphasizes the refinement of its once-a-week insulin patch and the optimization of its proprietary molecular designs. As the company navigates the complexities of the biotech landscape, it will likely focus on scaling its manufacturing capabilities and securing further partnerships to facilitate the commercialization of its therapeutic portfolio. The ongoing support from institutional investors and philanthropic organizations provides the necessary runway to navigate the rigorous regulatory environment, ensuring that these transformative diabetes treatments can eventually reach the patients who need them most.
See full Thermalin company page
